Ginkgo Bioworks

DNA

Market cap $520M

BOSTON , Nov. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year initiative funded by the Advanced Research Projects Agency for Health (ARPA-H). The collaboration, Microbe/phage Investigation for Generalized Health TherapY (MIGHTY), aims to develop innovative new treatments for oral health by leveraging Ginkgo's advanced capabilities in working with complex microbial consortia.

Ginkgo Bioworks shares dropped on Friday as revenue growth continues to disappoint and cash burn persists despite improvements. Q3 results missed expectations, with adjusted revenues tumbling and operating losses jumping thanks to a non-recurring charge taken. DNA's working capital is at its lowest point since coverage began, and recent equity sales have led to over 13% dilution in 18 months.

Ginkgo Bioworks Holdings, Inc. ( DNA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Daniel Waid Marshall Jason Kelly - Founder, CEO & Director Steven Coen - Chief Accounting Officer & CFO Presentation Daniel Waid Marshall [Audio Gap] Manager of Communications and Ownership at Ginkgo. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO.

Ginkgo provides an update on its third quarter financial results BOSTON , Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third quarter ended September 30, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Ginkgo and Partners to Develop Monoclonal Antibody Biomanufacturing Innovations and to Produce an Anti-Filovirus Medical Countermeasure BOSTON , Nov. 3, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to protect against and treat infection by filoviruses such as Ebola (EBOV) and Sudan Viruses (SUDV). The project has a total contract value of up to $22.2 million and seeks to deploy these innovations to produce the anti-filovirus mAbs cocktail of 1C3 and 1C11, discovered and developed by Emory University.

BOSTON , Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of biological products for agriculture. With the extension of this partnership, which began in 2017, both parties will build on the success of their ongoing collaboration to develop innovative microbial nitrogen fixation.

Presentation and Q&A session scheduled for post-market on Thursday, November 6, 2025 BOSTON , Oct. 30, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $12.74, signifying a -4.85% move from its prior day's close.

Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseases BOSTON , Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body ( EMBODY ) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D.

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.78, marking a -2.67% move from the previous day.